Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Leukemia. 2013 Oct;27(10):2081-3. doi: 10.1038/leu.2013.165. Epub 2013 Jun 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cell Transformation, Neoplastic / pathology*
  • Female
  • Follow-Up Studies
  • GTP Phosphohydrolases / genetics*
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology
  • Male
  • Membrane Proteins / genetics*
  • Middle Aged
  • Mutation / genetics*
  • Myelodysplastic Syndromes / genetics*
  • Myelodysplastic Syndromes / mortality
  • Myelodysplastic Syndromes / pathology
  • Prognosis
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • Retrospective Studies
  • Survival Rate
  • Young Adult
  • fms-Like Tyrosine Kinase 3 / genetics*
  • ras Proteins / genetics*

Substances

  • KRAS protein, human
  • Membrane Proteins
  • Proto-Oncogene Proteins
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • GTP Phosphohydrolases
  • NRAS protein, human
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins